SCHEMBL4678752

SCHEMBL4678752

CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(NC(=O)OC(C)(C)C)CC4)c3n2)COC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 3/20 0.73
IRAK4 Q9NWZ3 2/20 0.73
FLT3 P36888 2/20 0.73
GAK O14976 1/20 0.73
RIPK2 O43353 1/20 0.73
ULK1 O75385 1/20 0.73
STK10 O94804 1/20 0.73
PRKD3 O94806 1/20 0.73
LATS1 O95835 1/20 0.73
PAK4 O96013 1/20 0.73
NTRK1 P04629 1/20 0.73
LCK P06239 1/20 0.73
CDK1 P06493 1/20 0.73
APRT P07741 1/20 0.73
RET P07949 1/20 0.73
PDGFRB P09619 1/20 0.73
PHKG2 P15735 1/20 0.73
NQO2 P16083 1/20 0.73
PDGFRA P16234 1/20 0.73
FECH P22830 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27044759 0.94 MAP4K4 (0.68) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL30775090 0.94 MAP4K4 (0.68) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL25297847 0.91 MAP4K4 (0.64) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL29450826 0.91 MAP4K4 (0.64) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL3842680 0.87 IRAK4 (0.52) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL5766532 0.86 MAP4K4 (0.54) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL5765302 0.85 GAK (0.52) MAP4K4IRAK4FLT3GAKRIPK2
Morpholine SCHEMBL5764394 0.85 IRAK4 (0.52) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL30775118 0.85 CDK2 (0.63) MAP4K4IRAK4FLT3GAKRIPK2
SCHEMBL27045536 0.85 CDK2 (0.63) MAP4K4IRAK4FLT3GAKRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107382984-B Preparation method of medicine for treating leukemia 扬州市三药制药有限公司 2020-07-10 CN claimed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
CN-107382983-B Synthesis method of medicine for treating leukemia 扬州市三药制药有限公司 2020-08-07 CN disclosed
CN-107382984-B Preparation method of medicine for treating leukemia 扬州市三药制药有限公司 2020-07-10 CN disclosed
CN-107382984-B Preparation method of medicine for treating leukemia 扬州市三药制药有限公司 2020-07-10 CN disclosed
EP-1641780-B1 PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES PFIZER PROD INC (US) 2008-11-12 EP disclosed
EP-1641780-B1 PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES PFIZER PROD INC (US) 2008-11-12 EP disclosed
US-20070088032-A1 Processes for the Preparation of Benzoimidazole Derivatives TOM NORMA J 2007-04-19 US disclosed
US-7183414-B2 Processes for the preparation of benzoimidazole derivatives PFIZER INC (US) 2007-02-27 US disclosed
US-7183414-B2 Processes for the preparation of benzoimidazole derivatives PFIZER INC (US) 2007-02-27 US disclosed
EP-1641780-A1 PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES Pfizer Products Incorporated (US) 2006-04-05 EP disclosed
US-20050020625-A1 Processes for the preparation of benzoimidazole derivatives PFIZER INC 2005-01-27 US disclosed
WO-2004113322-A1 PROCESSES FOR THE PREPARATION OF 1-[(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088032-A1 Processes for the Preparation of Benzoimidazole Derivatives CCNI, CCNT1, CCNE1 MAP4K4 1296/4885IRAK4 1084/4885FLT3 498/4885
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS SGK1, SGK2, SIK1 MAP4K4 47/4885IRAK4 431/4885FLT3 1688/4885
US-20050020625-A1 Processes for the preparation of benzoimidazole derivatives CCNI, CCNT1, CCNE1 MAP4K4 1379/4885IRAK4 1108/4885FLT3 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.